Clinical trials: Glial Tumors
Glioblastoma Multiforme
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with…
- Trial name
- NCT02704858
- Testing
- Perillyl alcohol
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Neonc Technologies, Inc.
Brain and Central Nervous System Tumors
Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Boron neutron capture therapy and radiation therapy use high-energy x-rays and other types of radiation to kill tumor cells.
- Trial name
- NCT00974987
- Testing
- BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment), TMZ(temozolomide)
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Glioblastoma
Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme
Rationale of the Study: Treatment for GBM currently consists of surgical resection of the tumour mass followed by radio- and chemotherapy ((1)Stupp et al., 2005).
- Trial name
- DENDR1 (NCT04801147)
- Testing
- Dendritic Cells Vaccine
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Brain Tumor, Glioma
Gliogene: Brain Tumor Linkage Study
The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a…
- Trial name
- NCT00418899
- Testing
- Questionnaire
- Where
- 15 sites in United States, Denmark and 4 more
- Volunteers
- 17,080 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Glioblastoma
Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.
- Trial name
- NCT01364064
- Testing
- TMZ
- Volunteers
- 1,153 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Glioma
Seizure Treatment in Glioma
Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studies supporting the use of one specific anticonvulsant in glioma patients.
- Trial name
- STING (NCT03048084)
- Testing
- Levetiracetam, Valproic Acid
- Where
- 5 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Leiden University Medical Center
Glioblastoma
Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
- Trial name
- NCT04417933
- Testing
- Tumor Electric Fields Treatment System
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Recurrent Glioblastoma Multiforme (GBM)
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with…
- Trial name
- NCT00290771
- Testing
- Imatinib tablets, Hydroxyurea capsules
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- Novartis
Medulloblastoma, WNT-activated
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
This clinical study is going to be done on a type of brain tumor in children called Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and have the best outcomes in terms of survival.
- Trial name
- FOR-WNT2 (NCT04474964)
- Testing
- Low dose Craniospinal Irradiation plus Focal Radiotherapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Tata Memorial Centre
Glioblastoma Multiforme
Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)
Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab.
- Trial name
- NCT00817284
- Testing
- bevacizumab and Irinotecan and radiotherapy, Bevacizumab and Temozolomide and radiotherapy
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Ulrik Lassen
Glioblastoma Multiforme
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase) and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at pharmacodynamically active concentrations.
- Trial name
- NCT02850744
- Testing
- PQR309
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- PIQUR Therapeutics AG
Adult Glioblastoma
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Glioblastomas are extremely resistant to treatment, including radiotherapy and/or chemotherapy. Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation…
- Trial name
- GLYRad (NCT02364206)
- Testing
- LY2228820, Temozolomide, radiotherapy
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Centre Jean Perrin
Recurrent Glioblastoma, Brain Tumor
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
- Trial name
- NCT00503204
- Testing
- Cediranib, Lomustine
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Glioblastoma
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.The treatment outcomes, however, are still…
- Trial name
- NCT04157478
- Testing
- Anlotinib Hydrochloride, Radiation therapy, Temozolomide
- Where
- 7 sites in China
- Volunteers
- 464 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
In this research study the investigators want to learn more about the effects, both good and bad, when the study drug Ribociclib is given after radiation therapy.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
- Trial name
- NCT02607124
- Testing
- Ribociclib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Adult Brain Glioblastoma, Adult Gliosarcoma
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
This phase I/II trial studies the side effects and best dose of epidermal growth factor receptor bispecific antibody (EGFRBi)-armed autologous T cells and how well it works in treating patients with glioblastoma that have come…
- Conditions
- Adult Brain Glioblastoma, Adult Gliosarcoma, Recurrent Brain Neoplasm
- Trial name
- NCT02521090
- Testing
- EGFRBi-Armed Autologous T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Glioblastoma
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
In prior trials of CMV RNA-pulsed dendritic cell vaccines, there has been a narrow window between surgery and initiation of chemoradiation to enroll patients and perform leukapheresis (to obtain cells needed to generate…
- Trial name
- NCT04963413
- Testing
- Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Brain and Central Nervous System Tumors
Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients receiving radiation therapy and chemotherapy may help doctors learn more about the effects of this treatment on cells.
- Trial name
- NCT01233479
- Testing
- systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure
- Where
- 11 sites in United States
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.